Schedule of Components of Income Tax Expense (Benefit) |
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
|
|
|
|
|
|
Tax provision (benefit)
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
|
Federal
|
|
$
|
—
|
|
$
|
—
|
State
|
|
|
—
|
|
|
—
|
Total current
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
Deferred
|
|
|
|
|
|
|
Federal
|
|
|
(3,481,6764)
|
|
|
(2,141,153)
|
State
|
|
|
(1,416,877)
|
|
|
(6,146,506)
|
Total deferred
|
|
|
(4,898,641)
|
|
|
(8,287,659)
|
|
|
|
|
|
|
|
Change in valuation allowance
|
|
|
4,898,641
|
|
|
8,287,659
|
Total
|
|
$
|
—
|
|
$
|
—
|
|
Schedule of Deferred Tax Assets and Liabilities |
Deferred tax assets consisted of the following at December 31:
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
|
|
|
|
|
|
Deferred tax assets
|
|
|
|
|
|
|
Federal net operating loss
|
|
$
|
30,179,562
|
|
$
|
28,261,717
|
Federal research and development tax credit carryforwards
|
|
|
7,063,702
|
|
|
6,137,842
|
State net operating losses and tax credit carryforwards
|
|
|
4,393,526
|
|
|
3,590,961
|
Capitalized research and development expenses
|
|
|
9,911,446
|
|
|
8,955,425
|
Stock-based compensation expense
|
|
|
2,459,336
|
|
|
2,333,551
|
Depreciable assets
|
|
|
—
|
|
|
—
|
Other
|
|
|
419,597
|
|
|
292,259
|
Total deferred tax assets
|
|
|
54,427,169
|
|
|
49,571,755
|
|
|
|
|
|
|
|
Deferred tax liabilities
|
|
|
|
|
|
|
Depreciable assets
|
|
|
(110,705)
|
|
|
(153,928)
|
Total deferred tax liabilities
|
|
|
(110,705)
|
|
|
(153,928)
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
|
54,316,463
|
|
|
49,417,827
|
Less- valuation allowance
|
|
|
(54,316,463)
|
|
|
(49,417,827)
|
Total deferred tax assets
|
|
$
|
—
|
|
$
|
—
|
|